Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) – Equities research analysts at Leerink Swann upped their Q3 2018 earnings per share (EPS) estimates for shares of Trillium Therapeutics in a report released on Wednesday, November 14th. Leerink Swann analyst J. Chang now expects that the biotechnology company will post earnings of ($0.69) per share for the quarter, up from their prior forecast of ($0.78). Leerink Swann also issued estimates for Trillium Therapeutics’ Q4 2018 earnings at ($0.78) EPS, FY2018 earnings at ($2.42) EPS and FY2019 earnings at ($1.34) EPS.
A number of other research analysts also recently issued reports on the company. HC Wainwright set a $10.00 price objective on Trillium Therapeutics and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 11th.
Shares of NASDAQ:TRIL opened at $2.90 on Friday. Trillium Therapeutics has a 12-month low of $2.28 and a 12-month high of $13.30.
Several large investors have recently made changes to their positions in the stock. Wealth Alliance Advisory Group LLC bought a new position in shares of Trillium Therapeutics during the 3rd quarter valued at approximately $126,000. Stanley Laman Group Ltd. boosted its stake in Trillium Therapeutics by 26.7% in the 2nd quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock worth $823,000 after purchasing an additional 28,907 shares during the period. Renaissance Technologies LLC boosted its stake in Trillium Therapeutics by 245.3% in the 2nd quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 102,300 shares during the period. Finally, Baker BROS. Advisors LP boosted its stake in Trillium Therapeutics by 25.0% in the 2nd quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock worth $3,071,000 after purchasing an additional 102,440 shares during the period. Institutional investors own 47.90% of the company’s stock.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.